Full Text PAR-97-102 NINDS CLINICAL TRIAL PLANNING GRANT NIH Guide, Volume 26, Number 29, August 29, 1997 PA NUMBER: PAR-97-102 P.T. Keywords: National Institute of Neurological Disorders and Stroke PURPOSE The NINDS seeks to fund high quality clinical trials to evaluate treatments for neurological disorders. The NINDS Clinical Trial Planning Grant allows for early peer review of the rationale and design for clinical trials of treatments for neurological disorders and provides support for the development of a detailed clinical trial research plan, including a complete manual of operations and procedures. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, THE NINDS CLINICAL TRIAL PLANNING GRANT, is related to the priority area of chronic disabling conditions. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202- 512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT The mechanism of support will be the Developmental Planning Grant (R21), which will provide up to $150,000 in direct costs for a single year. The award cannot be renewed. RESEARCH OBJECTIVES The NINDS encourages clinical research to evaluate interventions to treat and prevent neurological disease. The NINDS has established the Clinical Trial Planning Grant because extensive efforts are required to develop a detailed study protocol and to organize an effective research group. After the basic design and rationale for a neurological treatment trial has been reviewed, the NINDS Clinical Trial Planning Grant supports the development of specific elements which will be essential to conducting a successful full-scale clinical trial, including adequate plans for recruitment of patients, experimental design and protocols, data management, analytical techniques, facilities, administrative procedures, and collaborative arrangements. Detailed information regarding the rationale of the clinical trial, based on adequate, preclinical science and preliminary clinical research, must be developed prior to submission and included in the application for a Clinical Trial Planning Grant. The purpose of the planning grant is not to obtain preliminary data or to conduct studies to support the rationale for the clinical trial. The expected product of the planning grant is a detailed clinical trial research plan including a complete manual of operations and procedures. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 20, 1994 (FR 59 14508-14513) and in the NIH Guide for Grants and Contracts, Vol. 23, No. 11, March 28, 1994. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95) and will be accepted at the standard application deadlines as indicated in the application kit. Applications kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267, email: [email protected]. The title and number of the program announcement must be typed in Section 2 on the face page of the application. As with most applications to NIH, the research plan is limited to 25 pages. All information for review of the NINDS Clinical Trial Planning Grant application must be included in the body of the application; appendices will not be considered during the review for this mechanism. The completed original application and four legible copies must be sent or delivered to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892 BETHESDA, MD 20817 (for express/courier service) In order to facilitate the review of applications assigned to the NINDS, the applicant should, at the same time, mail or deliver one copy of the application to: Dr. Lillian Pubols Chief, Scientific Review Branch NINDS, NIH Federal Building, Room 9C10 7550 Wisconsin Avenue Bethesda, Maryland 20892-9175 EMAIL: [email protected] REVIEW CONSIDERATIONS Applications will be assigned on the basis of established Public Health Service guidelines. Applications that are complete will be evaluated for scientific and technical merit by an appropriate peer review group convened in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council or board. Review Criteria: All applications will be reviewed using the criteria below: (1) Rationale. The background and significance of the application must address the rationale for a future, full-scale, randomized clinical trial (RCT) including: - reasons for selection of intervention and mode of delivery including specific details such as dose or a particular procedure; - the biological mechanisms and clinical data that support conducting an RCT; - information adequate to determine the significance and need to perform an RCT; - compelling need to proceed with an RCT as soon as possible; impact on health care; - competitive therapies--advantages and disadvantages; - ethical issues surrounding an RCT and the disease under study; - a clear statement of the question that an RCT would address. (2) Experimental Design. The application for a planning grant will include a full description of the experimental design of the future RCT, including: - translation of the clinical question into a statistical hypothesis; - sample size and duration of the RCT; - endpoint(s) and data to be collected; - randomization, masking, and inclusion/exclusion criteria; - the strengths and weaknesses of the proposed methods, and possible alternatives; - ancillary therapies - capability to develop methods for standardization of procedures for data management and quality control. (3) Plans to Address Patient Recruitment/Retention. The application must address the following items: - plans for documenting the availability of the requisite eligible- patient pool; - plans for including women and minority individuals as trial participants - and plans for recruitment outreach, as appropriate; follow-up procedures to ensure collection of data at stated intervals. (4) Investigators. The application must include a clear statement of the leadership and proposed organization of the RCT, including: - identification of a principal investigator, and for multi-center trials, a core of potential center investigators; - professional training and experience of the RCT organizers in such areas as the clinical problem under study, administration of complex projects, and study design. - inclusion of statisticians, data managers and study coordinators; - plans to add or drop centers; essential committee structure, i.e., Planning, Steering, Executive. AWARD CRITERIA Applications will compete for available funds with all other approved applications assigned to that IC. The following will be considered in making funding decisions: Quality of the proposed project as determined by peer review, availability of funds, and program priority. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Joseph S. Drage, M.D. Training and Special Programs Officer, National Institute of Neurological Disorders and Stroke Telephone: (301) 496-4188 FAX: 301-402-0302 Email: [email protected] Direct inquiries regarding fiscal matters to: Ms. Angeline Wilson Grants Management Branch National Institute of Neurological Disorders and Stroke Telephone: (301) 496-9231 FAX: 301-402-0219 Email: [email protected] AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.853. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||